Question special
Lead Moderator

Thank you all for your excellent participation so far. This question will mark the halfway point in our discussion. In the accompanying NEJM editorial by Dr. Connors, she notes that nonneutralizing antibodies were seen in 17% of participants, and observes that this may have an impact on subsequent administration of andexanet. As we all know, patients who have bleeding events, often have re-bleeding events, and it is not unlikely that a patient will need to receive multiple treatments with adnexanet. If there is a concern that adnexanet may have decreasing efficacy after the inital dose, this may lead clinicians to switch to warfarin or dabigatran after a bleeding event on rivaroxaban or apixaban. Can you please comment on the importance of these antibodies and whether they will likely be clinically important.